Navigation Links
Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
Date:12/16/2008

Synvista Therapeutics Technology Provided CML Biomarker Data for Studies

MONTVALE, N.J., Dec. 16 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced two publications demonstrating findings from studies that indicated that the presence of the advanced glycation end product (A.G.E.) called carboxymethyl-lysine (CML) in older adults is associated with a decline in renal function and arterial stiffness in older adults. Kits developed through a license to Synvista's technology were used in these studies. Synvista is validating this clinical diagnostic assay as it prepares to submit a CML kit for 510(k) clearance in the second half of 2009.

"These studies represent an important next step in our understanding of the role of CML in an elderly population, and they provide physicians more information that may be useful in the prevention of cardiovascular and renal disease, particularly in older adults," said Richard D. Semba, M.D., M.P.H, W. Richard Green Professor of Ophthalmology, The Johns Hopkins University School of Medicine and lead author of both studies. "As we have learned, the elevation of CML is preventable in many cases, as it can be mitigated by changes in diet. Therefore, to bring a clearer understanding of this A.G.E. to the forefront may help doctors better explain to their patients how to help prevent cardiovascular and renal complications."

In one study, published in a recent edition of American Journal of Hypertension, investigators measured 493 adult subjects participating in the Baltimore Longitudinal Study of Aging for their aortic pulse wave velocity (an index of aortic stiffness) and CML (using Synvista's proprietary technology). Results demonstrated that elevated levels of CML in these subjects corresponded to increased arterial stiffness, a known predictor of cardiovascular disease.

T
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
2. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
3. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
4. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
5. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
6. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
7. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
8. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
9. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:7/10/2014)... severe illness and even death are likely to result ... influenza. Now, however, a team of researchers based at ... the order of infection, the bacteria Streptococcus pneumoniae ... bad case of the flu. , The researchers ... as a bacterial virulence factor, might protect macrophagesa type ...
(Date:7/10/2014)... cancer were more likely to be diagnosed with ... and survived for shorter times than prostate cancer ... has found. , The negative outcomes may be ... against the mentally ill, depression,s impact on biological ... in his general health and disinterest in receiving ...
(Date:7/10/2014)... who experience hot flashes are unlikely to talk much ... silent suffering if they are willing to try ... University case study., After seven weeks of hypnotic relaxation ... following prostate cancer surgery showed a drastic decrease not ... in sleep quality, according to the study., The Baylor ...
(Date:7/9/2014)... the first time, researchers have access to detailed information ... health care. A new study, called Our Health Counts, ... challenges faced by urban Aboriginal people in Canada ... The findings, published today in BMJ Open , ... the general population. , Researchers interviewed 554 First Nations ...
(Date:7/9/2014)... active in almost all types of cancer sends the ... help fuel a tumour,s uncontrolled growth, new research suggests. ... identified a molecular trigger responsible for ratcheting up activity ... that makes the building blocks cancer cells need to ... pathway, called SREBP, controls the flow of messages to ...
Breaking Medicine News(10 mins):Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Urban Aboriginal people face unique health challenges 2Health News:Signal may send cancer's cellular factories into overdrive 2
... $10,000 Donation to Local Food Bank, WASHINGTON, Oct. ... Roundy,s Supermarkets Inc. have launched a,campaign to demonstrate the ... campaign will be conducted in 155 Pick ,n Save, ... 7-31, 2007., Shoppers can sample a smoothie recipe ...
... Agency recently honored Proctor & Gamble, Cincinnati, Ohio, ... risks., The company accepted a 2007 Children,s ... with the Children,s Environmental Health,Workshop in Washington D.C. ... to ensure clean drinking water for children by ...
... MARKET FORECAST FOR THE DRUG, WALTHAM, Mass., Oct. ... is available to discuss the impact of the Food ... integrase inhibitor drug which blocks the ability of the ... inhibitors are a novel class of HIV drugs aimed ...
... Central venous catheters are commonly used to provide permanent ... inserting a catheter through large vessels, has been commonly ... in Hemodialysis International finds that this treatment may block ... vena cava syndrome (SVC syndrome), a highly serious complication ...
... pleased to,announce the launch of a 5-year cooperative agreement ... of the program is to strengthen,the breadth and depth ... health informatics and encourage new explorations of innovations,at the ... to:, -- Train and educate the public health ...
... Ariz., Oct. 12 Langford IC Systems, Inc.,announces ... the only,Parametric Release(TM) liquid chemical instrument processor. The ... system that cleans and,reprocesses instruments at the point ... hospitals, medical clinics, and in any medical setting ...
Cached Medicine News:Health News:AISI and Roundy's Supermarkets Inc. Launch Program to Educate Shoppers on the Nutritional and Safety Benefits of Canned Food 2Health News:Proctor & Gamble Receives EPA Children's Environmental Health Excellence Award 2Health News:Impending FDA Approval Decision on the First HIV Integrase Inhibitor Can Have Significant Impact for Patients 2Health News:AMIA Announces Partnership with CDC to Enhance Public Health Informatics 2Health News:FDA Grants Clearance to Langford IC Systems, Inc. 2Health News:FDA Grants Clearance to Langford IC Systems, Inc. 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: